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Adherence and health-related quality of life
in adolescent liver transplant recipients
Non-adherence to post-transplant medical regi-
mens is estimated to be as high as 50–65%
among pediatric LT recipients (1, 2). The clinical
and economic consequences of transplant-related
non-adherence have the potential to be quite
substantial. It has been estimated that non-
adherence is related increased medical complica-
tions, graft rejection, post-transplant mortality,
and increased health care utilization rates (3–5).
Adolescence is a particularly high-risk period
for non-adherence with medical regimens (6, 7).
The developmental tasks associated with adoles-
cence, including developing autonomy from
family, assimilating with peers and separating
from parents, poorly developed abstract thinking
and understanding long-term consequences of
present actions, are often difficult to balance with
the behaviors required for optimal regimen
adherence (8). Indeed, among adolescent trans-
plant populations, medication non-adherence has
been reported to be more than four times greater
than in adults (9). A recent review of the
prevalence of non-adherence among adolescent
LT recipients revealed that non-adherence
ranged from 17% to 53% (mean = 36.3%) (10).
These non-adherence rates are striking given that
unlike other post-transplant complications,
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Abstract: Adolescence is a particularly high-risk period for non-
adherence with post-transplant medical regimens. There remains a lack
of research investigating factors related to non-adherence in adolescent
LT recipients. The present study empirically assessed the relationship
between adherence and HRQOL in adolescent LT recipients. Partici-
pants included 25 adolescents (mean = 15.1 yr, range 12–17.9) and
their parent/guardian(s). Adherence was assessed using multiple indices
including clinician-conducted interviews, rate of clinic attendance, and
s.d. of consecutive tacrolimus blood levels. HRQOL was examined
using self-report and parent-proxy report on well-validated assessment
measures. Results indicated that 76% of participants were non-adherent
on at least one measure of adherence, and HRQOL was significantly
lower than normative data for healthy children. Tacrolimus s.d. were
significant related to poor HRQOL across domains of physical, school,
and social functioning. Non-adherent adolescents reported poorer
health perceptions, self-esteem, mental health, family cohesion, and
more limitations in social and school activities related to physical,
emotional, and behavioral problems. These results suggest that empir-
ically based assessment of HRQOL may help identify those at highest
risk for behavior, emotional and school difficulties, as well as non-
adherence. The examination of tacrolimus s.d. may also help identify
patients who may benefit from intervention to promote adherence and
HRQOL. Prospective investigations are necessary to further identify the
impact of HRQOL on adherence and long-term health outcomes to
further guide clinical intervention.
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adherence behavior has the potential to be
directly modifiable.
Despite a growing recognition of the severity
of adherence problems during adolescence, the
assessment and treatment of non-adherence in
this population remains challenging. Existing
studies of adherence in pediatric transplantation
are limited by a lack of an accepted ‘‘gold
standard’’ method for assessing adherence. Pati-
ent/caregiver self-reports of adherence may be
the most cost-effective and easiest way to mon-
itor adherence (11, 12); however, self-reported
medication adherence is often less accurate (13),
and the concordance with objective measures and
health outcomes varies widely (14). Electronic
medication monitoring technology, such as the
MEMS (Aprex Corporation, Union City, CA,
USA), is the recommended assessment measure
in adherence research given its ability to provide
continuous and long-term measurement of med-
ication adherence in real-time, and can reveal
patterns of underdosing, overdosing, delayed
dosing, drug ‘‘holidays,’’ and ‘‘white coat adher-
ence’’ (i.e., taking medications consistently be-
fore medical appointments) (15). The MEMS
have demonstrated relationships between mea-
sured adherence and health outcomes such as
viral load in children with HIV/AIDS (16). Yet,
there are barriers associated with the MEMS
technology including cost and the possibility that
these devices may interfere with established
adherence routines (17). Recent studies have
attempted to measure adherence objectively
using a measure of the fluctuation (i.e., s.d.) of
medication blood levels of tacrolimus in pediatric
LT recipients (9, 18, 19). Higher s.d. were
predictive of clinical outcome, such as biopsy-
proven rejection (9) and hospitalization rates (19)
in children who had undergone liver transplan-
tation. However, there are limitations to relying
on blood serum levels as a measure of adherence
given that they are subject to pharmacokinetic
variations. Until there is an accepted gold stan-
dard for measuring adherence in transplantation,
it may be useful to employ a multi-method
assessment strategy (12, 20).
In addition to developing valid strategies to
measure adherence, it is also necessary to identify
variables that promote regimen adherence
among pediatric LT recipients. Research with
other pediatric chronic illness populations has
identified poor HRQOL as a key construct
related to non-adherence (7, 21). To date, there
remains a lack of research examining the rela-
tionship between HRQOL and non-adherence
among adolescent LT recipients. Moreover, fur-
ther exploration of HRQOL in adolescent trans-
plant recipients is warranted given the challenges
associated with this developmental period.
Results from previous studies examining
HRQOL in pediatric LT recipients have yielded
equivocal results. Some studies report that pedi-
atric LT recipients have poorer quality of life in
areas of physical, psychological, social, and
family functioning when compared with healthy
peers, but equal to or better HRQOL than
children with other chronic illnesses (22–25).
However, a recent study of adolescent HRQOL
following liver or kidney transplantation
revealed that the level of overall physical and
psychological functioning among adolescent
transplant recipients was high, and most aspects
of HRQOL were similar to a healthy school-
based population (26). These studies have not
examined the relationship between HRQOL and
adherence to post-transplant regimens.
A recent study by our group examined the
association between HRQOL and non-adherence
in pediatric LT recipients. Non-adherence, as
measured by tacrolimus s.d. and rate of clinic
attendance, was related to lower physical
HRQOL, more limitations in social and school
activities, and decreased family cohesion (19).
However, the average age of the study sample was
8.6 yr, thus little is known about the relationship
between HRQOL and non-adherence in adoles-
cents. Adolescence is a high-risk period for non-
adherence, thus it is critical to focus on this
population in studies of adherence (6). The aims
of this study are to examine rates of adherence to
post-transplant regimens using multiple assess-
ment methods, empirically assess HRQOL using
parent-proxy and adolescent self-report, and
clarify the relationship between adherence and
HRQOL in adolescent LT recipients. It is
hypothesized that adolescents with poorer adher-
ence will have poorer HRQOL.
Materials and method
Study population
Participants were recruited from the Pediatric
Liver Transplant Clinic at the University of
Michigan, (Ann Arbor, MI, USA). Adolescent
LT recipients between the ages of 12 and 17 yr
were eligible for participation if they were fluent
in English, and if they had at least one parent/
guardian willing to participate as well. Partici-
pants were excluded if they were actively being
treated for post-transplant lymphoproliferative
disorder or other malignancy, had undergone a
solid organ transplantation other than liver
transplantation (i.e., kidney), or if they had
significant developmental delay (i.e., documented
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IQ < 70). Patients who had undergone retrans-
plantation were eligible for participation in this
pilot study.
Procedures
This study was a cross-sectional assessment of
LT recipients between the ages of 12 and 17 yr.
All aspects of the study were approved by the
Institutional Review Board of the University of
Michigan Medical School, and study enrollment
began in November 2006. Informed consent and
adolescent assent were obtained for all partici-
pants. Parent/guardian(s) and adolescents com-
pleted standardized assessment measures of
HRQOL during a Pediatric Liver Transplant
Clinic visit. Demographic, medical, and adher-
ence data were obtained from a demographic
survey, the adolescents hospital medical record,
the University of Michigans OTIS, and an
adherence questionnaire. Parents and adolescents
were each compensated for their time and effort
devoted to study-related activities at a rate of $25
(USD) each. Parents and adolescents also
received meal tickets and parking vouchers.
Measures
HRQOL
Two measures of HRQOL were used in the
present study as there is considerable variability
in the literature regarding HRQOL, and no
measure has been demonstrated to have more
clinical utility or predictive validity. Thus, two
measures were used to determine which was most
associated with measures of adherence and
health outcomes. At this time, there are no
validated transplant-specific measures to assess
HRQOL in pediatric populations.
PedsQL 4.0-generic core scales: The PedsQL4.0
Core Scales (27) is a well-validated, 23-item
modular instrument for measuring HRQOL in
children and adolescents ages 2–18 yr, and allows
for a comparison of HRQOL across acute and
chronic health conditions, and with healthy chil-
dren (27). The healthy child normative compari-
son group included healthy children who were
assessed either in physicians offices during well-
child checks or by telephone and whose parents
did not report the presence of a chronic health
condition. Administration time is approximately
five min. Parent-proxy report and adolescent
self-report were measured for all participants.
The PedsQL assesses HRQOL across 4 domains:
Physical, Emotional, Social, and School function-
ing. Total, Physical, and Psychosocial Sum-
mary scores are also calculated. Scores are
transformed to a 0–100 scale, with higher scores
indicating more positive HRQOL.
CHQ: Parents completed the CHQ-PF50 and
adolescents completed the CHQ-CF87 (28). The
CHQ-PF50 is a 50-item scale, and the CHQ-
CF87 is an 87-item scale. Both forms assess a
broad spectrum of child- and family-focused
health areas including: Physical Functioning,
Role/Social Limitations – Physical, General
Health Perceptions, Bodily Pain/Discomfort,
Role/Social Limitations-Emotional/Behavioral,
Parent Impact-Time, Parent Impact-Emotion,
Self-Esteem, Mental Health, Behavior, Family
Activities, Family Cohesion, and Change in
Health. Administration time is approximately
15–20 min. Items are responded on a 4- or 5-
point Likert scale depending on the subscale.
Scores are transformed to a 0–100 scale, with
higher scores indicating better health. The CHQ-
PF50 has been normed using a representative
sample of U.S. children (28), while the normative
sample used for the CHQ-CF87 is a school-based
population (n = 278) comprised predominately
(92%) of African American children aged 10–
15 yr (29). Representative U.S. population nor-
mative data for the CHQ-CF87 are unavailable.
Adherence behavior
A multi-method assessment of adherence was
employed to measure adherence to immunosup-
pressive medication and clinic visits. Definitions
of adherence were determined using stringent
cut-offs based on previous research showing that
minimal deviations from dosing schedules of the
immunosuppressive regimens were associated
with an increase risk of poor clinical outcomes
(30, 31).
Clinician-conducted interview: Adolescents com-
pleted the MAM (Zelikovsky, unpublished data),
as a self-report measure of adherence to immu-
nosuppressive medication. The MAM is a semi-
structured interview assessing knowledge of
medical regimen, self-reported adherence, per-
ceived obstacles to adherence, and the system
used to organize medications. This measure has
been used with pediatric solid organ transplant
recipients (32–34). Adherence was defined as
adolescent report of missing/taking late <10%
of any medication in the previous seven days,
and/or adolescent report of not missing a dose
within the previous two wk.
Clinic attendance: Adherence to clinic visits
was assessed retrospectively by comparing clinic
attendance to the number and interval
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frequency recommended by the transplant team.
The rate of clinic attendance for the year prior
to study participation was obtained from the
adolescents medical record. Adherence was
defined as a clinic attendance rate of ‡90%.
This definition is consistent with the pediatric
adherence literature (35). In our previous study
of pediatric LT recipients, the rate of clinic
attendance was significantly related to hospital
admissions, liver biopsies, and rejection epi-
sodes (19).
Immunosuppressant levels: To measure adher-
ence to post-transplant immunosuppressant
medications, data from routine monitoring of
tacrolimus blood levels were obtained from the
adolescents medical record and OTIS for the
year prior to study participation. Tacrolimus
levels obtained during inpatient hospitalization
stays were not included in the analyses. S.d. of
consecutive trough tacrolimus blood levels were
calculated. Shemesh and colleagues have demon-
strated the predictive and concurrent validity of
the use of s.d. of tacrolimus blood levels as a
measure of adherence to immunosuppressive
medications (9). Specifically, higher fluctuations
have been used as an indicator of variable
medication administration, and tacrolimus s.d.
significantly related to clinician ratings of non-
adherence, as well as health outcome including
episodes of rejection (9). In this study, adherence
was defined as s.d. < 2 (36).
Health status
Measures of adolescent health status including
frequency of hospital admissions, liver biopsies,
and episodes of rejection for the year prior to
study participation were collected via patient
electronic medical records and the University of
Michigan Universitys OTIS.
Statistical method
Sample mean subscale and summary scores
obtained on the HRQOL measures were com-
pared with published normative data for healthy
children using two-tailed t-tests. Pearson correla-
tion coefficients were used to assess the relation-
ships between scores on the HRQOL measures
and measures of adherence. Participants were
categorized as ‘‘adherent’’ or ‘‘non-adherent’’
based on their self-reported medication taking
behavior, rate of clinic attendance and tacrolimus
s.d. Two-sample t-tests were used to assess differ-
ences between ‘‘adherent’’ and ‘‘non-adherent’’
participants with respect to measures of HRQOL
and health outcomes. All analyses were
conducted using Statistical Package for the Social
Sciences (SPSS, Chicago, IL, USA) version 13.0.
Results
Participants
To date, 42 eligible participants have been
identified and recruited by mail and/or face-to-
face contact during their clinic visit. Of these
eligible participants contacted, 28 (66.7%) agreed
to participate. Fourteen families declined partic-
ipation due to time constraints, transportation
limitations, lack of interest, and/or the presence
of other children at the clinic visit. Three of the
adolescents enrolled in the study were not
receiving tacrolimus immunosuppressive ther-
apy. S.d. were not calculated for cyclosporine
as this method assumes that medication blood
levels are related to intake, which has been shown
to be the case for tacrolimus but not for
cyclosporine (37). Thus, only the 25 adolescents
who were receiving tacrolimus immunosuppres-
sive therapy are included in these analyses.
Table 1 describes the demographic character-
istics of the study group. The mean age of
adolescent LT recipients was 15.1 ± 1.9 yr
(range 12.0–17.9 yr), and the mean age at the
time of transplantation was 7.6 ± 5.6 yr (range
8 months–15.2 yr). The mean time elapsed since
transplantation was 7.5 ± 5.7 yr (range
1 month–17.2 yr). Primary indication for trans-
plantation was biliary atresia (48%) followed by
autoimmune hepatitis (20%), hepatitis (12%),
alpha-1 antitrypsin (8%), and other (12%).
Three patients had undergone retransplantation
Table 1. Participant demographics
Factor Mean € s.d.
Participant age (yr) 15.1 € 1.9
Time since transplantation (yr) 7.5 € 5.7
Age at transplantation (yr) 7.6 € 5.6
Maternal age (yr) 37.0 € 7.8
Paternal age (yr) 40.3 € 6.8
Parent-proxy respondent Mothers = 19 (76%)
Fathers = 5 (20%)
Other = 1 (4%)
Participant gender Female = 17 (68%)
Male = 8 (32%)
Participant race (parent-reported) White = 18 (72%)
African American = 7 (28%)
Diagnosis Biliary atresia = 12 (48%)
Fulminant hepatic failure = 1 (4%)
Autoimmune hepatitis = 5 (20%)
Hepatitis = 3 (12%)
Alpha-1 antitrypsin = 2 (8%)
Sclerosing cholangitis = 1 (4%)
Other = 1 (4%)
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within an average of 40 days (3–96 days) of their
initial transplantation for reasons including
primary non-function, chronic rejection, and
acute liver failure. The date of their second liver
transplantation was used for all study analyses.
Adolescents were predominately female (68%).
A majority of the parent/guardian respondents
were mothers (76%), half of whom were married
(52%), and most did not have more than a high
school education (44%).
There were no significant relationships bet-
ween time since transplantation, age at trans-
plantation, race or other demographic variables
and measures of psychosocial functioning, adher-
ence, or health status.
HRQOL
PedsQL
Mean HRQOL scores for the adolescent self-
report and parent-proxy are presented in Figs. 1
and 2 for both adolescent LT recipients and the
healthy normative sample (27). Both self-re-
ported and parent-proxy HRQOL scores were
impaired and significantly lower than published
normative data for healthy children. Parent-
proxy reports indicate marked impairment with
respect to Total Functioning (p = 0.0001), Phys-
ical (p = 0.006) and Psychosocial Health
(p = 0.0001), Emotional (p = 0.013), Social
(p = 0.02), and School Functioning
(p = 0.0001). Adolescent self-reports are indica-
tive of impairment in Total Functioning
(p = 0.007), Psychosocial Health (p = 0.01),
Emotional (p = 0.04), and School Functioning
(p = 0.001).
CHQ
Tables 2 and 3 present means and s.d. for the
subscales of the CHQ-PF50 and CHQ-CF87 for
LT recipients compared with published scores for
healthy children (28, 29). Results from the CHQ-
PF50 indicate that the Physical summary score
was significantly lower for LT recipients than for
the healthy comparison group (p = 0.012).
Compared with the healthy sample, parents
reported that their adolescent LT recipients had
significantly lower scores on the Self-Esteem
(p = 0.017) and General Health Perceptions
(p = 0.0001) subscales, and endorsed signifi-
cantly lower scores on the Parental Impact-
Emotional scale (p = 0.027), and the Family
Activities scale (p = 0.007). There were no
significant differences across remaining subscales.
In contrast, on the CHQ-CF87, self-reports
from the adolescent LT recipients were signifi-
cantly lower than the healthy sample on the
General Health Perceptions scale (p = 0.031),
but there were no significant differences across
remaining subscales.
Adherence behavior
Sixteen participants (76%) were non-adherent on
at least one measure of adherence. However,
there were no significant relationships between
measures of adherence behaviors, suggesting that
these assessment methods evaluate different
aspects of regimen adherence. With non-signifi-
cant correlations obtained between methods of
measurement (self-report vs. immunosuppressant
drug level), a composite adherence score was not
used. As such, participants were classified cate-
gorically as ‘‘adherent’’ and ‘‘non-adherent’’
























Fig. 1. PedsQL 4.0 parent proxy-report scores for adoles-
cent LT population and healthy children. Normative data
for healthy children were retrieved from published refer-
ences (42). The full range of the PedsQL 4.0 is 0–100, with
























Fig. 2. PedsQL 4.0 adolescent self-report scores for LT
population and healthy children. Normative data for heal-
thy children were retrieved from published references (42).





Adherence was defined as adolescent report of
missing/taking late <10% of any medication in
the previous seven days, and/or adolescent re-
port of not missing a dose within the previous
two wk. Ten adolescents (40%) were classified as
non-adherent based on reports of missed and/or
late doses of their immunosuppressive medica-
tion. Five participants (20%) stated they never
missed a dose of tacrolimus, while 10 participants
(40%) reported missing a dose within the past
two wk. Eight participants (32%) reported it had
been at least a month since they had missed a
dose. When asked about their medication taking
behavior in the week prior to study participation,
overall, patients missed an average of 3% of
weekly immunosuppressant doses (range 0–
21.4%) and took an average of 11.1% (range
0–100%) of the doses more than two h late.
Eighteen participants (72%) reported never miss-
ing a dose of tacrolimus, five participants (20%)
reported missing at least one dose in the previous
week, one adolescent (4%) reported missing at
least two doses, and one adolescent (4%)
reported missing three doses. Ten participants
(40%) reported never taking their tacrolimus
late, while five participants (20%) reported tak-
ing one dose late, seven participants (28%)
reported taking two doses late, two participants
(8%) reported taking three doses late, and one
participant (4%) reported taking 14 doses late
(i.e., being late with both doses every day).
Adolescents who did endorse missed or late doses
cited forgetting, not being home, interfered with
activities, and ran out of medication as reasons.
Immunosuppressant levels
Participants had an average of 10.5 ± 6.7 blood
levels of tacrolimus in the year prior to study
participation (range 4–29 blood values). The
mean tacrolimus s.d. was 1.9 ± 1.5 ng/mL
(range 0.21–7.32 ng/mL). Eight participants





(mean € s.d.) t-value Significance
Physical functioning 87.1 € 22.4 96.1 € 13.9 )2.003 p = 0.057
Role/Social – Emotional,
behavioral
81.3 € 32.8 92.5 € 18.6 )1.701 n.s.
Role/Social – Physical 85.3 € 27.8 93.6 € 18.6 )1.488 n.s.
Bodily pain 73.6 € 24.1 81.7 € 19.0 )1.678 n.s.
Behavior 77.7 € 15.5 75.6 € 16.7 0.677 n.s.
Mental health 77.6 € 12.4 78.5 € 13.2 )0.362 n.s.
Self-esteem 68.5 € 21.9 79.8 € 17.5 )2.574 p = 0.017
General health perceptions 55.6 € 16.6 73.0 € 17.3 )5.234 p = 0.000
Parental Impact – Time 80.1 € 26.2 87.8 € 19.9 )1.441 p = 0.0001
Parental Impact – Emotional 72.3 € 17.0 80.3 € 17.3 )2.348 p = 0.027
Family activities 81.0 € 14.8 89.7 € 18.6 )2.933 p = 0.007
Family cohesion 70.6 € 20.4 72.3 € 8.8 )0.417 n.s.
Physical functioning summary 45.3 € 13.8 53.0 € 8.8 )2.730 p = 0.012
Psychosocial functioning
summary
49.0 € 9.3 51.2 € 9.1 )1.133 n.s.
*Individual scores range from 0 to 100, with higher scores reflecting better HRQOL.
Data for healthy population were retrieved from published references (28).
Physical and psychosocial summary scales are standardized (mean = 50, s.d. = 10).
CHQ-PF, Child Health Questionnaire, Parent Form; HRQOL, health-related quality of life.
Table 3. CHQ-CF87 summary scores for liver transplant recipients compared





(mean € s.d.) t-value Significance
Physical functioning 90.2 € 14.1 88.8 € 14.0 0.504 n.s.
Role/Social-Emotional 87.6 € 20.9 85.9 € 21.0 0.397 n.s.
Role/Social – Behavioral 87.6 € 21.6 86.5 € 21.5 0.235 n.s.
Role/Social – Physical 88.4 € 21.9 88.3 € 21.0 0.033 n.s.
Bodily pain 72.4 € 23.7 74.4 € 23.1 )0.422 n.s.
Behavior 81.0 € 15.1 76.6 € 14.6 1.453 n.s.
Mental health 77.2 € 18.7 72.7 € 16.0 1.214 n.s.
Self-esteem 81.8 € 12.1 81.8 € 15.8 0.004 n.s.
General health
perceptions
60.3 € 13.3 66.4 € 14.6 )2.297 p = 0.031
Family activities 79.7 € 16.6 –
Family cohesion 68.6 € 22.8 –
*Individual scores range from 0 to 100, with higher scores reflecting better
HRQOL.
Data for healthy population were retrieved from published references (29).
The Family Activities and Family Cohesion subscales were unavailable for the
healthy sample.




(32%) were classified as non-adherent based on
tacrolimus s.d. > 2.
Clinic attendance
Participants attended an average of
85.8 ± 17.5% of scheduled clinic visits (range
50–100%). Twelve participants (48%) were clas-
sified as non-adherent based on a rate of clinic
attendance of <90%.
Health status
Within the 12 months prior to participation, nine
(36%) participants had been hospitalized at least
once, five (20%) underwent at least one liver
biopsy, and one (4%) had a documented biopsy-
proven episode of rejection. Overall, there were
16 hospital admissions, 40 inpatient days, eight
liver biopsies, and one biopsy-proven episode of
rejection.
Relationship between HRQOL and adherence behavior
Correlations with HRQOL
Tacrolimus s.d. was significantly related to mea-
sures of parent-proxy and adolescent self-
reported measures of HRQOL. Specifically,
tacrolimus s.d. was significantly related to par-
ent-proxy reports of adolescent school function-
ing on the PedsQL (r = )0.415, p = 0.039), and
several subscales of the CHQ-PF50 including:
Role/Social Limitations-Emotional-Behavioral
(r = )0.435, p = 0.030), Role/Social Limita-
tions-Physical (r = )0.672, p = 0.0001), Bodily
Pain/Discomfort (r = )0.619, p = 0.001), Men-
tal Health (r = )0.438, p = 0.029), General
Health Perceptions (r = )0.581, p = 0.002),
Physical Summary Score (r = )0.728, p =
0.001), and Parent Impact-Time (r = )0.547,
p = 0.006).
Tacrolimus s.d. was significantly related to
adolescent-self reports on numerous scales on
the PedsQL including Physical Functioning (r =
)0.550, p = 0.004), Social Functioning (r =
)0.397, p = 0.049), School Functioning
(r = )0.666, p = 0.001), and Total Functioning
(r = )0.471, p = 0.017). There were also signif-
icant relationships between tacrolimus s.d. and
several scales on the CHQ-CF87 including Phys-
ical Function (r = )0.798, p = 0.0001), Role/
Social Limitations-Physical (r = )0.453,
p = 0.023), General Health Perceptions
(r = )0.608, p = 0.001), Bodily Pain/Discom-
fort (r = )0.572, p = 0.003), and Family Cohe-
sion (r = )0.421, p = 0.036).
The MAM and rate of clinic attendance were
not significantly related to parent-proxy or ado-
lescent self-reports of HRQOL.
Differences between ``adherent'' and ``non-adherent''
participants
Based on the clinician-conducted interview and
the rate of clinic attendance, there were no
significant differences between the adherent and
non-adherent groups with respect to HRQOL.
However, based on tacrolimus s.d. classifications,
there were significant between-group differences
with respect to HRQOL (see Table 4). Specifi-
cally, parents in the non-adherent group reported
that their adolescents health had a greater
impact on their time (CHQ-PF50, p = 0.048)
than parents in the adherent group. Compared
with parents in the adherent group, parents in the
non-adherent group reported that their adoles-
cents had significantly lower scores on CHQ-
PF50 subscales measuring Role/Social Limita-
tions-Physical Functioning (p = 0.018), Bodily
Pain/Discomfort (p = 0.010), General Health
Perceptions (p = 0.007), and on the Physical
Summary Scale (p = 0.007).
In contrast, adolescents in the non-adherent
group reported significantly lower scores on all
domains of the PedsQL including Physical Func-
tioning (p = 0.001), Emotional Functioning
(p = 0.001), Social Functioning (p = 0.01),
School Functioning (p = 0.002), and Total
Functioning (p = 0.000). Adolescents in the
non-adherent group also reported significantly
lower scores than those in the adherent group on
several subscales of the CHQ-CF87 including
Physical Functioning (p = 0.004), Role/Social
Limitations-Physical (p = 0.008), General
Health Perceptions (p = 0.003), Bodily Pain
(p = 0.002), Role/Social Limitations-Emotional
(p = 0.018), Self-Esteem (p = 0.001), Mental
Health (p = 0.001), and Family Cohesion
(p = 0.038).
With respect to health outcomes, adolescents
classified as non-adherent based on tacrolimus
s.d. had significantly more hospital admissions
than the adherent group (p = 0.032) and more
inpatient days (p = 0.037). Participants in the
non-adherent group as defined by clinic atten-
dance also had significantly more hospital admis-
sions (p = 0.029) than the adherent group.
Discussion
The current study objectives were to describe
HRQOL and adherence to post-transplant regi-
mens using multiple assessment methods, and to
explore the links between adolescent HRQOL
and adherence to post-transplant regimens.
Results of the present study are consistent with
our previous research (19) and indicate that
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adolescent LT recipients and their parents
reported decreased HRQOL compared with
normative data for healthy children across var-
ious domains of functioning.
Based on parent-proxy reports, adolescent LT
recipients were perceived to have poorer physical,
social, school, and emotional functioning com-
pared with a healthy comparison group. More-
over, parents reported more impairment in
family activities and in their own emotional
functioning related to their adolescents trans-
plant than parents of the healthy comparison
group.
Adolescent self-reported HRQOL varied by
assessment measure. Based on the CHQ-CF87,
self-reports from the adolescent LT recipients
were significantly lower than the healthy com-
parison group on the General Health Perceptions
scale, but were comparable with the healthy
sample on remaining scales. Based on the Peds-
QL, with the exception of social functioning,
adolescents reported poorer HRQOL across
physical, emotional, and school functioning
domains compared with the healthy comparison
group. The findings using the CHQ are consistent
with previous research (26). The discrepancies in
HRQOL as measured by the PedsQL and the
CHQ may be related to variability in content
across domains, as well as the nature of norma-
tive comparison groups used. Both of these
instruments have psychometric support (27, 38,
39), but there is limited research using these
measures in pediatric transplantation. There is a
need for continued research examining HRQOL
of pediatric transplant recipients using validated
measures and age-matched controls. Moreover,
to date, there are no transplant-specific measures
of HRQOL validated for use in pediatric popu-
lations.
Despite the variability with respect to the
assessment of HRQOL, adolescent, and parent-
proxy reports of HRQOL were related to adher-
ence as measured by s.d. of tacrolimus blood
levels. Poorer HRQOL was significantly associ-
ated with greater variability in tacrolimus blood
levels, which is suggestive of medication non-
adherence. Tacrolimus s.d. were related to poorer
HRQOL across domains of physical, school, and
social functioning, and general health percep-
tions. Tacrolimus s.d. were also related to par-
ents reports of their adolescents mental health,
and parental perceptions of limitations their
adolescents have in school-related and social
activities due to problems with physical, emo-
tional, and behavioral functioning. Adolescent
self-reports of limitations in family cohesiveness
were also related to tacrolimus s.d.
There were significant differences in HRQOL
between adherent and non-adherent adolescents.
Parents in the non-adherent group only perceived
their adolescents to be more limited in their
school-related activities and activities with









CHQ-PF50 Parent Impact-Time 65.3 € 34.8 87.5 € 17.6 )2.098 0.048
CHQ-PF50 Role/Social – Physical 66.7 € 36.7 94.1 € 17.6 )2.558 0.018
CHQ-PF50 Bodily Discomfort 56.2 € 25.6 81.8 € 19.1 )2.794 0.010
CHQ-PF50 General Health Perceptions 43.1 € 13.9 61.4 € 14.7 )2.953 0.007
CHQ-PF50 Physical Summary 35.1 € 50.9 50.4 € 9.9 )2.957 0.007
Adolescent self-report
PedsQL Physical Functioning 64.8 € 13.7 84.9 € 11.3 )3.865 0.001
PedsQL Emotional Functioning 51.9 € 20.0 80.6 € 16.3 )3.828 0.001
PedsQL Social Functioning 72.5 € 19.3 88.8 € 10.1 )2.809 0.01
PedsQL School Functioning 50.8 € 11.6 71.8 € 12.6 )3.561 0.002
PedsQL Total Functioning 61.3 € 12.2 81.5 € 8.3 )4.864 0.000
CHQ-CF87 Physical Functioning 79.2 € 19.8 95.4 € 6.1 )2.915 0.004
CHQ-CF87 Role/Social – Physical 72.2 € 32.0 96.1 € 8.7 )2.915 0.008
CHQ-CF87 General Health Perceptions 49.4 € 12.8 65.4 € 10.4 )3.336 0.003
CHQ-CF87 Role/Social – Emotional 73.6 € 31.4 94.1 € 8.9 )2.539 0.018
CHQ-CF87 Bodily Pain 52.5 € 19.1 81.8 € 19.8 )3.490 0.002
CHQ-CF87 Self-Esteem 71.1 € 9.9 86.9 € 9.6 )3.807 0.001
CHQ-CF87 Mental Health 60.7 € 21.9 85.0 € 10.8 )3.756 0.001
CHQ-CF87 Family Cohesion 55.0 € 23.1 75.0 € 20.3 )2.199 0.038




friends caused by problems in physical health. In
contrast, based on adolescent self-report, adoles-
cents in the non-adherent group were more
impaired across all domains of HRQOL includ-
ing physical, emotional, social, and school func-
tioning. Non-adherent adolescents reported
poorer health perceptions, self-esteem, mental
health, and family cohesion, and endorsed more
school and social limitations due to physical,
emotional, and/or behavioral problems.
The results of this study should be considered
in light of study limitations. First, this study was
conducted within a single pediatric LT program
which limited the sample size and the ability to
generalize these findings to other pediatric LT
centers. To strengthen these findings, this re-
search should be replicated in pediatric trans-
plant centers across geographical locations.
Moreover, the sample may not be representative
due to a potential selection bias wherein patients
and families who are non-adherent did not elect
to participate. This selection bias is present in
many studies investigating regimen adherence
(21). Nevertheless, despite this potential selection
bias, the majority of adolescent participants were
non-adherent on at least one measure of adher-
ence behavior.
Another limitation relates to the retrospective,
cross-sectional study design. The current study
reports an association between HRQOL and
adherence, but the direction of these relation-
ships remains unclear as the retrospective,
cross-sectional nature of this study limits any
conclusions regarding causality. It is commonly
assumed that impaired HRQOL and psychoso-
cial adjustment contributes to poor regimen
adherence, however there is a lack of research
investigating these relationships longitudinally.
Overall, positive HRQOL and psychological
adjustment is associated with better treatment
adherence (7). However, research has also shown
that non-adherence is associated with more
frequent hospital admissions, longer hospital
stays, over-utilization of health care services,
and lower quality of life (40, 41). Indeed, non-
adherent adolescents in the present study had
more frequent and longer inpatient hospitaliza-
tions than the adherent adolescents. Thus, the
diminished HRQOL reported by adolescents in
the present study may be secondary to their
suboptimal adherence and subsequent poorer
health. Further work is needed to clarify the
relationship between HRQOL, adherence, and
medical variables as this has important implica-
tions for the development of interventions to
promote adherence and improve health out-
comes.
Lastly, these preliminary results are limited by
the lack of agreement between measures of
adherence. The current study implemented a
multi-method approach to assessing adherence
behavior; however, only tacrolimus s.d. were
significantly related to HRQOL. Previous re-
search has identified a relationship between
tacrolimus s.d. and clinical health outcomes (9,
19) and psychosocial functioning (18, 19). Yet,
there is limited research investigating the validity
of clinic attendance and patient self-report as
measures of adherence in adolescent transplant
recipients. Further study of the relationship
between measures of adherence and clinical
outcomes, including episodes of rejection, graft
function as well as psychosocial functioning, is
warranted.
Despite limitations, the present study is
strengthened by its significant clinical implica-
tions. Although this was a single center study
with a reasonably small sample size, significant
relationships were found between measures of
adherence and HRQOL. Non-adherence as
measured by tacrolimus s.d. was related to
aspects of HRQOL, including social, emotional,
and physical functioning. Empirically based
assessment of modifiable factors will help iden-
tify patients at risk for non-adherence, and may
allow for the appropriate delivery of interven-
tions to ameliorate this risk. Given that ado-
lescent self-reported HRQOL was associated
with adherence in the present study, routine
assessment of self-reported measures of
HRQOL from adolescent LT recipients may
help identify those at highest risk for behavior,
emotional, and school difficulties, as well as
non-adherence. Similarly, the routine examina-
tion of tacrolimus s.d. may also help identify
patients who are not only at-risk for non-
adherence, but who may benefit from interven-
tion targeting HRQOL. To further elucidate the
relationship between adherence and HRQOL
among adolescent LT recipients, prospective
longitudinal studies to identify impact of
HRQOL on adherence and health outcomes
are warranted.
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